PV Bulletin

Safety Signal Management Updates for RSV Bronchiolitis Treatments in France

Ongoing safety concerns and medication errors have been reported regarding treatments for RSV bronchiolitis, requiring enhanced vigilance from healthcare professionals.

Primary source: Consultez le rapport d'enquête de pharmacovigilance Beyfortus (30/09/2024)

Translated from French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

Add to My Intelligence

Sign in with your work email to save this update, triage it, and track follow-up.

Sign in to save

PV Impact Brief

Awareness · MediumConfidence: low

What changed

Increased emphasis on monitoring for medication errors in RSV treatments, as well as the initiation of a pharmacovigilance inquiry for VRS treatments starting May 26, 2023, whose data collection spans from March 1, 2025, to February 28, 2026.

Why it matters

Continued vigilance is crucial for ensuring patient safety and minimizing medication errors, which can significantly impact treatment outcomes in vulnerable populations such as infants with RSV bronchiolitis.

Action needed

Sign in to unlock the full action card and owner assignment.

Sign in with your work email to read the full operational brief, action card, and evidence ledger.

Continue reading with PV Bulletin

Sign in with your work email to unlock the full briefing, regulatory action card, evidence ledger, and role-specific next steps.

Related updates for your role

publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 25, 2026

Guidance on Real-World Data Collection for Regulatory Decisions

Awareness · Medium

PV teams should review and update their Standard Operating Procedures (SOPs) related to real-world data collection methodologies and ensure alignment with the new guidance emerging from the workshop. Training may also be required to enhance understanding of RWD's impact on regulatory submissions.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 25, 2026

Clarifications on Dossier Requirements for Biological Medicinal Products

Awareness · Medium

PV teams should update workflows and standard operating procedures (SOPs) to incorporate these clarified dossier requirements. Ensure that all biological product dossiers include necessary details as outlined by the new guidance and provide training to relevant staff on these changes.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 25, 2026

Enhanced Data Utilization and Standardization in EU Medicines Regulation

Awareness · Medium

PV teams should review and update Standard Operating Procedures (SOPs) to align with new EMA guidelines on data management, accessibility, and sharing. Ensure compliance with the security standards outlined by the EMA to protect sensitive data and maintain data integrity.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicTGA · Australia · Updated Sep 25, 2026

New Data Sharing Guidance to Manage Hospital Medicine Shortages

Awareness · Medium

PV teams should update workflows and SOPs related to signal management and compliance controls to incorporate new data-sharing protocols and strategies for managing medicine shortages.

Signal ManagementCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceMedium
Relevant for: Regulatory Intelligence Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward